The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. (Q38113416)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

V S Hoffmann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

M Baccarani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

D Lindoerfer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

F Castagnetti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

A Zaritsky

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

A Hellmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

W Prejzner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

J-L Steegmann

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

J Mayer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

K Indrak

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

A Colita

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

G Rosti

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

M Pfirrmann

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

11 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

2016-2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752173%20AND%20SRC:MED&resulttype=core&format=json

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Characteristics of accelerated disease in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

inferred from DOI database lookup

7 January 2021

based on heuristic

The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171

inferred from DOI database lookup

7 January 2021

based on heuristic

The EUTOS CML score aims to support clinical decision-making

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.171